ISSN (Print): 1567-2018
ISSN (Online): 1875-5704
Volume 17, 8 Issues, 2020
Download PDF Flyer
Open Access Funding
Promote Your Article
ISSN (Print): 1567-2018
ISSN (Online): 1875-5704
Aims & Scope
Science Citation Index Expanded, InCites, BIOSIS Previews, BIOISIS Reviews Reports and Meetings, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE, Chemical Abstracts Service/SciFinder, ProQuest, ChemWeb, Google Scholar, Media Finder®-Standard Periodical Directory, Genamics JournalSeek, PubsHub, Index Copernicus, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO, British Library, Ulrich's Periodicals Directory and JournalTOCs.
Ranking and Category:
Submit Abstracts / Manuscripts Online
Animated Abstract Submission
Xing-Jie Liang CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety National Center for Nanoscience and Technology of China Beijing P.R. China
View Full Editorial Board
5 - Year: 1.709
Order Your Article Before Print
Self Archiving Policies
Instructions for Authors
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
"For many drugs, delivery is as big a challenge as development. Current Drug Delivery provides essential information for all drug scientists."
Jhon de Jersey
The Univ. of Queensland, Australia
Bioactive molecules based nano-formulations for therapy and Drug development
Guest Editor(s): Dr. Meiwan Chen, Dr. Liangzhu Feng, Dr. Xingjie Liang
Tentative Publication Date: December, 2020
Submit Abstract via Email
Drug Delivery Australia
Guest Editor(s): Mariusz Skwarczynski, Ben Boyd
I would like to thank the entire editing team of the Current Drug Delivery for their commitment to resolve all issues regarding the publication of my article. All sectors work in consonance and are quite agile.
I believe that my work is of interest both in the pharmaceutical industry and in the biotechnology industry, since once the bioavailability of the active substance is guaranteed at its site of action, the better is the result for the patient. And so it is in the interest of the whole chain of health goods production, to encourage them to study this issue of biopharmaceutical stability in depth.
At the moment I am working with ophthalmic release systems, which is still in progress. I look forward to future contributions to your journal.
Aline Gravinez Perissinato (LACFAR, Institute of Chemistry, Federal University of Alfenas, Alfenas, Brazil.)
Has contributed: Simple Strategy to Protect Lactase Activity in Solid Formulation.
5 Abstract Ahead of Print are available electronically
10 Articles Ahead of Print are available electronically
This special issue of Current Drug Delivery combines the research topics presented during Controlled Release Asia Meeting
2018 in Singapore (24th & 25th September 2018, Venue: Matrix Building – Biopolis, Singapore), hosted by the Australian chapter
of Controlled Release Society, co-organized and supported by Core-NET (Controlled Release and Encapsulation Network
led by Agency for Science, Technology and Research (A*STAR) at Singapore) and regional Chapters of the Controlled Release
Society. The issue is entitled “Drug Delivery Asia”; however, the content is not limited to the Asian research. The meeting provided
an excellent opportunity for knowledge exchange between participants from Asia and around the world. This issue contains
contributions from a variety of areas in the field of drug and vaccine delivery.
The large number of biological active compounds failed to be developed into drugs due to their poor bioavailability .
Many of them, like genes, peptides and proteins, are too large and too hydrophilic to pass biological membranes . Especially,
oral absorption and poor in vivo stability are major hurdles that have to be overcome for biological active compounds to reach
clinical trials [3, 4]. Problem with off target delivery of drugs is the other common hindrance. To overcome all these obstacles
variety of drug and vaccine delivery systems have been developed. The drug and vaccine candidates can be modified by conjugation
with lipidic moieties to balance their hydrophobicity resulting in improved passive diffusion and uptake into the lymphatic
system [5-7]. In contrast, the saccharide moieties can be conjugates to reduce excessive hydrophobicity of compounds
and improve their water-solubility, or to utilise active transport systems using certain receptors ability to recognize saccharides
and uptake them into the cells, or utilize to target the drug to the desired site of action [8-11]. Improved bioavailability of the
large or hydrophilic molecules can be also achieved with the help of formulations and by the use of cell penetrating peptides
[12, 13], surfactants [14, 15], or polyelectrolytes (such as alginate or chitosan) [16-19]. Nanotechnology-based approaches are
also becoming extensively popular in the drug and vaccine delivery field [20-22]. These strategies take advantage of nanomaterials
ability to a) selectively deliver a therapeutic agent to the desired tissue [23, 24], b) protect a cargo from harsh environment
(e.g. in stomach) and enzymatic degradation (in intestine, blood) [25, 26], c) improve compounds uptake by immune cells when
desired, or reduce this uptake [27, 28], d) allow variety of delivery pathways including oral [29, 30], intranasal [31-33] and intradermal
[17, 34, 35].
This Current Drug Delivery issue comprises both original research reports and review papers focused on the various aspects
of delivery systems mentioned above. The review articles describe the role of carbohydrates in vaccine delivery and development
(Aljohani et al.), as well as targeted gene delivery (Begum et al.). Intraperitoneal (Padmakumar et al.) and oral (Hussain
et al.) delivery strategies of the common chemotherapeutic agent paclitaxel are discussed. The original research articles describe
also the utilization of nanotechnology in amphotericin delivery (Tiyaboonchai et al.) and application of magnetic nanoparticles
for tracking inflammation in the epileptic rat brain (Eyal et al.). The role of polysaccharide chitosan in nanoparticlesbased
drug delivery (Hamid et al. and Sahudin et al.) and the application of lipophilic tocopherol-based carrier for co-enzyme
Q10 formulation (Boyd et al.) are also presented. Finally, oral delivery of antibiotic sirolimus (C.) and the role of mucilages as
pharmaceutical excipients (Gugulothu et al.) are investigated.
These variety of research topics should make this issue of special interest for all the readers of Current Drug Delivery.
No Text Found